ZentiMGAltomariALupoMGet al.From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol2018; 25: 1843–1851.
2.
OttoCGeissHCEmpenKet al.Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis2004; 174: 151–156.
3.
AdorniMPZimettiFPuntoniMet al.Cellular cholesterol efflux and cholesterol loading capacity of serum: Effects of LDL-apheresis. J Lipid Res2012; 53: 984–989.
4.
SbranaFBigazziFDal PinoBet al.Elusive therapeutic effect of PCSK9 inhibitors on lipoprotein(a) levels. Ther Apher Dial. Epub ahead of print 11 October 2018. DOI: 10.1111/1744-9987.12766.
